ABT-202

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
ABT-202
ABT-202.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC9H13N3
Molar mass163.219 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2][3]

References[edit]

  1. ^ Jain KK (January 2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
  2. ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  3. ^ Xu N, Kim GE, Gregg H, Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA (September 2004). "Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–95. doi:10.1016/j.jpba.2004.05.013. PMID 15351065.